ALB
EstablishedAlbumin is a liver-made blood protein whose low levels signal poor nutrition, liver disease, or severe illness.
Albumin is a protein made by the liver that carries substances around the blood and keeps fluid in blood vessels. Low albumin is a red flag in many different illnesses — not just liver or kidney disease — and often signals a sicker overall patient, regardless of the specific diagnosis.
Albumin is the most abundant plasma protein, synthesized by the liver, responsible for maintaining oncotic pressure and transporting hormones, drugs, and minerals. Its level reflects nutritional status, liver synthetic function, and systemic inflammation.
Low albumin (hypoalbuminemia) is associated with malnutrition, liver disease, kidney protein loss, and critical illness, but is increasingly recognized as an independent prognostic marker across oncology broadly — predicting worse outcomes in acute myeloid leukemia, immune checkpoint inhibitor response, and general hospitalized-patient mortality regardless of underlying disease.
Measured via routine serum chemistry panel; a 2022 study found hypoalbuminemia predicted higher 1-year mortality (OR 4.49) in hospitalized medical patients independent of the underlying condition prompting admission.
Pretreatment albumin is factored into composite prognostic scores (e.g., Glasgow Prognostic Score, multiple myeloma ISS staging) to guide risk stratification and treatment intensity decisions.
A broad, independent prognostic marker across many diseases, not just liver or kidney disorders.
- Doucette, K., et al. (2021). Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia. Hematological Oncology.
- Levit, L., et al. (2022). Serum Hypoalbuminemia Is a Long-Term Prognostic Marker in Medical Hospitalized Patients. J. Clin. Med.